TY - JOUR
T1 - Adrenal mitochondrial benzodiazepine receptors are sensitive to agents active at the dopamine receptor
AU - Amiri, Zamir
AU - Katz, Yeshayahu
AU - Weizman, Abraham
AU - Bidder, Miri
AU - Snyder, Solomon H.
AU - Gavish, Moshe
N1 - Funding Information:
~c&no~~e~ge~en~-~iws ork was supportedb y grant 00234fr om the U.S.-Israel BinationalS cienceF oundation. This paper is submitted in partial fulfilment of the requirementfso r theD Sc. degreeo f Z.A. at theT echnion-Israel Institute of Technology. We thank the National Instituteo f Diabetesa nd Digestivea nd Kidney Diseases, National Institutes of Health, as we11a s the National Hormone and Pituitary Program, University of Maryland School of Medicine, for providing materialsf or the rat PRL immunoassaayn d Ruth Singerf or typinga nd editing the manuscript.
PY - 1993/3/9
Y1 - 1993/3/9
N2 - Male rats were treated for 21 days with drugs known to affect prolactin secretion, in order to assess the effects of these drugs on mitochondrial benzodiazepine receptors (MBRs). Sulpiride, a selective dopamine D2 receptor antagonist and hyperprolactinemic agent, decreased MBR density in the adrenal gland (49%;P < 0.005), whereas metoclopramide, another dopamine antagonist with a preference for dopamine D2 receptors, increased adrenal gland MBR density (31%; P < 0.05). Bromocriptine, a specific dopamine agonist, increased MBR density in this organ (87%; P < 0.001). None of the three agents influenced kidney or testicular MBRs. These data indicate that the mechanism of organ-specific alterations in MBRs seems to be prolactin independent.
AB - Male rats were treated for 21 days with drugs known to affect prolactin secretion, in order to assess the effects of these drugs on mitochondrial benzodiazepine receptors (MBRs). Sulpiride, a selective dopamine D2 receptor antagonist and hyperprolactinemic agent, decreased MBR density in the adrenal gland (49%;P < 0.005), whereas metoclopramide, another dopamine antagonist with a preference for dopamine D2 receptors, increased adrenal gland MBR density (31%; P < 0.05). Bromocriptine, a specific dopamine agonist, increased MBR density in this organ (87%; P < 0.001). None of the three agents influenced kidney or testicular MBRs. These data indicate that the mechanism of organ-specific alterations in MBRs seems to be prolactin independent.
UR - http://www.scopus.com/inward/record.url?scp=0027478438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027478438&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(93)90242-O
DO - 10.1016/0006-2952(93)90242-O
M3 - Article
C2 - 8384854
AN - SCOPUS:0027478438
SN - 0006-2952
VL - 45
SP - 999
EP - 1002
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 5
ER -